FortuneRock (China)

About FortuneRock (China)

FortuneRock (China) Co., Ltd. is a clinical-stage biotechnology company headquartered in Beijing, China, that was founded in 2010. The company, chaired by Prof. Zailin YU, focuses on the research, development, and commercialization of patented, gene-based recombinant protein drugs for treating life-threatening and debilitating diseases. FortuneRock operates through its subsidiaries, including Tianjin SinoBiotech Ltd., SinoBiotech (Tianjin) Ltd., and Beijing Bio-Fortune Ltd.

The company's core technology is its Long Acting Recombinant Protein Drug Platform, which is used to develop therapeutic protein drugs with a longer half-life, reducing the frequency of injections for patients. Its most advanced candidate is a long-acting treatment for chemotherapy-induced neutropenia (CIN), which has completed Phase II clinical trials. Another key candidate for Hepatitis B and C has completed Phase I trials. FortuneRock's technology utilizes a High Efficacy Yeast Expression System Platform, enabling the production of large quantities of high-quality recombinant protein products. The company holds numerous patents for its technology platforms in the US and China.

FortuneRock has a history of strategic financial and licensing activities. In June 2013, it sold non-exclusive U.S. rights for a patented technology to a major pharmaceutical company. In August 2014, the company raised $24 million in a Series B funding round to support a new subsidiary and prepare for an initial public offering. Subsequently, on July 30, 2015, FortuneRock announced its IPO on the National Equities Exchange and Quotations (NEEQ) in China, trading under the ticker NEEQ:833178.